Lessons from mouse models in the impact of risk factors on the genesis of childhood B-cell leukemia

Front Immunol. 2023 Oct 12:14:1285743. doi: 10.3389/fimmu.2023.1285743. eCollection 2023.

Abstract

B-cell acute lymphoblastic leukemia (B-ALL) stands as the primary contributor to childhood cancer-related mortality on a global scale. The development of the most conventional forms of this disease has been proposed to be conducted by two different steps influenced by different types of risk factors. The first step is led by a genetic insult that is presumably acquired before birth that transforms a healthy cell into a preleukemic one, which is maintained untransformed until the second step takes place. This necessary next step to leukemia development will be triggered by different risk factors to which children are exposed after birth. Murine models that recap the stepwise progression of B-ALL have been instrumental in identifying environmental and genetic factors that contribute to disease risk. Recent evidence from these models has demonstrated that specific environmental risk factors, such as common infections or gut microbiome dysbiosis, induce immune stress, driving the transformation of preleukemic cells, and harboring genetic alterations, into fully transformed leukemic cells. Such models serve as valuable tools for investigating the mechanisms underlying preleukemic events and can aid in the development of preventive approaches for leukemia in child. Here, we discuss the existing knowledge, learned from mouse models, of the impact of genetic and environmental risk factors on childhood B-ALL evolution and how B-ALL prevention could be reached by interfering with preleukemic cells.

Keywords: B-ALL; childhood leukemia; environmental factors; genetic predisposition; mouse models; risk factors.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Child
  • Humans
  • Leukemia, B-Cell*
  • Leukemia, Lymphocytic, Chronic, B-Cell*
  • Mice
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / etiology
  • Risk Factors

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Research in CV-D group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). Research in IS-G group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE; by RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20), by the Fundacion Unoentrecienmil (CUNINA project), and by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC). AC-G (CSI067-18), MI-H (CSI021-19) and BR-C are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019, 2020, and 2022 (ESF, European Social Fund) fellowship, respectively. SA-A is supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887). LS is supported by a scholarship from the University of Salamanca co-financed by Banco Santander and ESF.